A detailed history of New York State Common Retirement Fund transactions in Igm Biosciences, Inc. stock. As of the latest transaction made, New York State Common Retirement Fund holds 6,512 shares of IGMS stock, worth $112,397. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,512
Previous 6,512 -0.0%
Holding current value
$112,397
Previous $45,000 140.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$6.51 - $11.47 $117 - $206
18 Added 0.28%
6,512 $45,000
Q4 2023

Feb 01, 2024

SELL
$3.94 - $8.79 $130 - $290
-33 Reduced 0.51%
6,494 $54,000
Q3 2023

Nov 07, 2023

BUY
$6.66 - $10.64 $359 - $574
54 Added 0.83%
6,527 $55,000
Q2 2023

Aug 07, 2023

SELL
$8.86 - $14.0 $194 - $308
-22 Reduced 0.34%
6,473 $60,000
Q4 2022

Jan 30, 2023

BUY
$15.45 - $26.02 $92 - $156
6 Added 0.09%
6,495 $110,000
Q3 2022

Nov 08, 2022

BUY
$15.42 - $27.01 $570 - $999
37 Added 0.57%
6,489 $148,000
Q2 2022

Aug 04, 2022

SELL
$13.27 - $25.5 $238 - $459
-18 Reduced 0.28%
6,452 $116,000
Q1 2022

May 05, 2022

BUY
$13.42 - $29.73 $40 - $89
3 Added 0.05%
6,470 $173,000
Q4 2021

Feb 02, 2022

SELL
$27.59 - $66.39 $386 - $929
-14 Reduced 0.22%
6,467 $190,000
Q3 2021

Nov 02, 2021

SELL
$65.76 - $90.65 $90,617 - $124,915
-1,378 Reduced 17.53%
6,481 $426,000
Q2 2021

Aug 02, 2021

BUY
$57.98 - $96.6 $78,794 - $131,279
1,359 Added 20.91%
7,859 $654,000
Q2 2020

Aug 07, 2020

BUY
$51.3 - $75.21 $102,600 - $150,420
2,000 Added 44.44%
6,500 $475,000
Q4 2019

Feb 05, 2020

BUY
$17.25 - $49.51 $77,625 - $222,795
4,500 New
4,500 $172,000

Others Institutions Holding IGMS

About IGM Biosciences, Inc.


  • Ticker IGMS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,969,000
  • Market Cap $500M
  • Description
  • IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...
More about IGMS
Track This Portfolio

Track New York State Common Retirement Fund Portfolio

Follow New York State Common Retirement Fund and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New York State Common Retirement Fund, based on Form 13F filings with the SEC.

News

Stay updated on New York State Common Retirement Fund with notifications on news.